Navigation Links
Juvenile Diabetes Research Foundation Names Monye Connolly Corporate Chair for its Annual Walk to Cure Diabetes
Date:3/4/2009

The 2009 Walk to Cure Diabetes will be held Saturday, October 17 at

Centennial Olympic Park

ATLANTA, March 4 /PRNewswire/ -- The Georgia Chapter of the Juvenile Diabetes Research Foundation (JDRF) has announced that Blue Cross and Blue Shield of Georgia (BCBSGa) President, Monye Connolly, will serve as the Corporate Chair for its annual, and largest, fundraising event, Walk to Cure Diabetes. The event is scheduled in Atlanta at Centennial Olympic Park on Saturday, Oct. 17, 2009.

Last year's walk raised more than $1.5 million to fund research to help find a cure for diabetes.

"The Juvenile Diabetes Research Foundation is firm in its commitment to finding a cure for diabetes and its complications through the support of research. BCBSGa truly believes in JDRF and its mission, which supports our mission of improving the lives of the people we serve and the health of our communities," said Connolly.

"We look forward to working with Monye Connolly in the months to come to make the 2009 Walk our best one ever. As someone with type 1 diabetes myself, it is very gratifying to have the support of such a large, successful company in our relentless goal to find a cure for diabetes and its complications," said Kris Bagwell, JDRF Georgia Board President

As many as 3 million people in the U.S. are now living with type 1 diabetes. Each year more than 15,000 children are diagnosed with diabetes - that's 40 children per day. More than 85 percent of JDRF's expenditures directly support research and research-related education.

Corporate sponsorships, corporate Walk Teams and Family Walk Teams will be the key to the success of the Walk to Cure Diabetes. For more information about JDRF, the critical research they fund and how you can help, call 404-420-5990, or visit www.jdrf.org.

About JDRF:

JDRF was founded in 1970 by the parents of children with type-1 diabetes - a disease that strikes children, adolescents and adults suddenly, making them insulin dependent for life, which carries the constant threat of devastating complications. Since inception, JDRF has provided more than $1.3 billion to diabetes research worldwide. More than 85 percent of JDRF's expenditures directly support research and research-related education. JDRF's mission is constant: to find a cure for diabetes and its complications through the support of research. To register now and participate, sponsor an event, build a walk team, or for more information, please visit www.jdrf.org, or call 404-420-5990.

About Blue Cross Blue Shield of Georgia:

Blue Cross and Blue Shield of Georgia, Inc. and Blue Cross and Blue Shield Healthcare Plan of Georgia, Inc. are independent licensees of the Blue Cross and Blue Shield Association(R) . The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Additional information about Blue Cross and Blue Shield of Georgia is available at www.bcbsga.com.


'/>"/>
SOURCE Juvenile Diabetes Research Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pennsylvanians May Donate Part of Tax Refund to Support Juvenile Diabetes Research
2. Etanercept, Methotrexate Safe for Juvenile RA
3. Second Annual Eye Ball Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology
4. University of South Florida receives new multimillion award to assess juvenile diabetes treatments
5. Drug May Ease Symptoms of Juvenile Arthritis
6. Pediatric researchers find possible master switch gene in juvenile arthritis
7. Early life infections increase the risk of rheumatoid arthritis and juvenile idiopathic arthritis
8. Specific mutations in the IL2RA gene associated with juvenile idiopathic arthritis
9. Chrysler LLC Vice Chairman and President Jim Press and His Wife Suwichada Serve as Honorary Co-Chairs of Annual Juvenile Diabetes Research Foundation Promise Ball
10. Study affirms effectiveness of medication for juvenile rheumatoid arthritis
11. Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: